YMDD变异与ALT、HBeAg及HBV DNA的关系
摘要
本研究对拉米夫定治疗过程中发生病毒突破的68例慢性乙型肝炎患者行HBVYMDD变异检测，并分析拉米夫定治疗乙型肝炎过程中出现的YMDD变异状况及相关的临床结果。
出处
《肝脏》
2012年第3期212-213,共2页
Chinese Hepatology
参考文献12
-
1Marrone A,Zampino R,Luongo G. Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic Hepatitis B virus infection[J].Intervirology,2003.222-226.doi:10.1159/000072431.
-
2Stuyver LJ,Locarnini SA,Lok A. Nomenclature for antiviralresistant human hepatitis B virus mutations in the polymerase region[J].Hepatology,2001.751-757.doi:10.1053/jhep.2001.22166.
-
3Delaney WE,Locarnini S,Shaw T. Resistance of hepatitis B virus to antiviral drugs:current aspects and directions for future investigation[J].Antiviral Chemistry & Chemotherapy,2001.1-35.
-
4Ogata N,Fujii K,Takigawa S. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B[J].Journal of Medical Virology,1999.270-276.doi:10.1002/(SICI)1096-9071(199911)59:3<270::AID-JMV2>3.0.CO;2-1.
-
5Nafa S,Ahmed S,Tavan D. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B[J].Hepatology,2000.1078-1088.doi:10.1053/jhep.2000.19619.
-
6Hadziyannis SJ,Papatheodoridis GV,Dimou E. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B[J].Hepatology,2000.847-851.doi:10.1053/jhep.2000.17915.
-
7Kobayashi S,Ide T,Sara M. Detection of YMDD motif mutation in some lamivudine-untreated asymptomatic hepatitis B virus carriers[J].Journal of Hepatology,2001,(4):584-586.doi:10.1016/S0168-8278(00)00023-4.
-
8At kins M,Hunt CM,Brown N. Clinical significance of YMDD mutant hepatitis B virus in a large cohort of lamivudine-treated hepatitis B patients[J].Hepatology,1998.319A.
-
9Nafa S,Ahmed S,Tavan D. Early detection of Viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B[J].Hepatology,2000.1078-1088.doi:10.1053/jhep.2000.19619.
-
10Lok AS,Lai CL,Leung N. Long-term safety of lamivudine treatment in patients with chronic hepatitis B[J].Gastroenterology,2003.1714-1722.doi:10.1053/j.gastro.2003.09.033.
二级参考文献9
-
1Atkins M, Hunt CM, Brown N, et al. Clinical significance of YMDD mutant hepatitis B virus in a large cohort of lamivudine-treated hepatitis B patients (abstract). Hepatology, 1998, 28: 319A.
-
2Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis Be antigen seroconversion rates: results after 3 years of therapy.Hepatology, 2001, 33: 1527-1532.
-
3Nafa S, Ahmed S, Tavan D, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology,2000, 32: 1078-1088.
-
4Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology,2003, 125: 1714-1722.
-
5Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol, 2000, 32: 300-306.
-
6Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology, 2003, 124:105-117.
-
7Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology, 2004, 126: 81-90.
-
8侯金林,孙剑.乙型肝炎病毒核苷类似物耐药性监测和预防及其处理[J].中华医学杂志,1999,79(11):806-807. 被引量：15
-
9张欣欣,韩永年,陆志檬,张东华.乙型肝炎病毒多聚酶变异与拉米夫定治疗反应[J].中华传染病杂志,2001,19(1):15-18. 被引量：46
共引文献27
-
1杨芳,王磊.第011例 乙肝肝硬化核苷(酸)类似物相关多重耐药突变1例分析[J].中国医学前沿杂志（电子版）,2011,3(1):87-88.
-
2Professional Staff Committee of Combination Therapy of Chronic Hepatitis B.Chinese Consensus on Combination Therapy of Chronic Hepatitis B[J].国际感染病学（电子版）,2012,1(1):58-64.
-
3刘中宏,李春明,王秀江,龙培滨.胃癌微转移基因检测的临床应用[J].世界华人消化杂志,2004,12(9):2033-2035. 被引量：5
-
4陆德云,王甦,赵连三.影响拉米夫定相关乙肝病毒YMDD变异的因素[J].世界华人消化杂志,2005,13(18):2243-2245. 被引量：15
-
5王晶波,王磊,李晓迎,杜以真,王耀宗.拉米夫定治疗儿童和青少年慢性乙型肝炎的长期临床观察[J].肝脏,2005,10(4):275-277. 被引量：3
-
6文睿,王坚,严明.中药降肝隆联合拉米夫定治疗活动性肝炎90例[J].世界华人消化杂志,2005,13(20):2509-2513. 被引量：2
-
7李威,申元英.乙型肝炎病毒基因变异及临床意义[J].国际流行病学传染病学杂志,2006,33(6):396-398. 被引量：3
-
8许诚,杨桂林,徐六妹,姚红艳,乐晓华,李美忠,蒋小玲,钟菊珍,王敏,王火生,周伯平.慢性乙型肝炎患者YMDD变异合并前C/C区启动子变异的临床研究[J].中国基层医药,2007,14(7):1057-1059. 被引量：1
-
9王磊.慢性乙型肝炎的诊治新标准——解读我国《慢性乙型肝炎防治指南》[J].山东医药,2007,47(26):119-120. 被引量：8
-
10梁雪松,万谟彬.慢性乙型肝炎长期抗病毒治疗的耐药管理[J].中华内科杂志,2007,46(9):780-783. 被引量：2
-
1高建平,杨国宗,梁建平,郑瑞丹,徐卫平.拉米夫定治疗HBeAg阳性和阴性慢性乙型肝炎探讨[J].临床消化病杂志,2002,14(4):176-177. 被引量：2
-
2石铭,韩博.拉米夫定治疗过程中影响HBV YMDD变异的相关因素分析[J].中国冶金工业医学杂志,2009,26(2):224-225.
-
3邱源旺,黄利华,蒋祥虎,胡泰洪,丁虹,蒋跃明,戴亚新,周敏.HBV YMDD变异者采用阿德福韦和恩替卡韦治疗144周临床比较[J].肝脏,2011,16(5):370-372.
-
4白红莲,罗红涛,严海明,杨光,梁东.乙型肝炎病毒基因型与YMDD变异的关系[J].首都医药,2008,15(18):31-32.
-
5张友定,徐朝峰.慢性乙型肝炎患者HBV YMDD变异临床相关因素的研究[J].肝脏,2005,10(2):149-150. 被引量：1
-
6白留江.乙型肝炎患者YMDD变异62例临床特点分析[J].肝脏,2007,12(4):322-323.
-
7祝英华,石铭,韩博,张卓然.乙型肝炎患者肝组织损害程度与YMDD变异的相关[J].中国微生态学杂志,2007,19(2):225-225.
-
8李春明,张跃新.HBVYMDD拉米夫定耐药变异及其检测的研究进展[J].国外医学（病毒学分册）,2003,10(2):56-60.
-
9蒋孝华,蔡亚平,刘映霞,李红梅,唐武成.拉米夫定治疗引起HBVYMDD变异的检测及临床意义[J].中国现代医学杂志,2007,17(3):321-323. 被引量：1
-
10许家璋,张馨,谢琴秀,李平,杨志国.HBV YMDD变异相关因素的分析及防治对策[J].传染病信息,2006,19(3):116-118.
